Graft Polymer (UK) PLC (LSE:GPL) CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the company's promising preclinical program targeting mental health conditions such as post-traumatic stress disorder (PTSD). Partnering with Eurofins Discovery, Graft Polymer is testing its co-lead aminoindane series, a class of compounds that interact with serotonin, dopamine, and norepinephrine receptors. These compounds aim to reduce the human response to trauma, addressing the significant unmet need in PTSD treatment. "Unfortunately, PTSD affects millions, with 13 million sufferers in the U.S. alone," Tennyson explained, adding that current treatments are limited, leaving a large addressable market. With Eurofins Discovery's expertise in research services, Graft Polymer is moving forward quickly and expects preclinical results by the end of November. Watch the full interview for insights into this groundbreaking PTSD research and stay updated on Graft Polymer’s progress. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to give this video a like, subscribe to the channel, and enable notifications for future updates. #GraftPolymer #AnthonyTennyson #EurofinsDiscovery #PTSDTreatment #PharmacologyTesting #MentalHea#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews